Follow The Filings

ZNTL Zentalis Pharmaceuticals

Zentalis Pharmaceuticals earnings company data as of 4:47 AM ET 10/22

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by ZNTL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ZNTL insider trades
  • $22.9M bought by 1 insider
  • $10M sold by 1 insider outside a trading plan
  • $18K sold by 1 insider under 10b5-1 plans
  1. Walters Group 10% owner, +2 joint filers
    Buy
    $15.2M 4,335,000 shares at $3.50 +32% to stake
    Traded Aug 14 Filed Aug 19
  2. Vincent Vultaggio PAO and PFO
    Planned sale
    $17K 6,894 shares at $2.42 4.5% of stake
    Traded Feb 10 Filed Feb 10
  3. Vincent Vultaggio PAO and PFO
    Planned sale
    $1,398 556 shares at $2.52 0.3% of stake
    Traded Feb 3 Filed Feb 4
  4. Walters Group 10% owner, +2 joint filers
    Buy
    $7.8M 6,459,973 shares at $1.20 +92% to stake
    Traded Dec 31, 2025 Filed Jan 8
  5. Matrix Capital Management Company, LP 10% owner, +1 joint filer
    Sale
    $10M 7,500,000 shares at $1.33 54% of stake
    Traded Dec 15, 2025 Filed Dec 15, 2025

Also filed in the last 12 months, not counted as buying or selling: 7 stock grants and 7 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
424B5
8-K 8.01,9.01
SCHEDULE 13G/A —
424B5
8-K 2.02,7.01
10-Q
SCHEDULE 13G —
8-K 5.07
8-K 5.02
DEFA14A
8-K 7.01,8.01
8-K 2.02,7.01
10-Q
8-K 7.01,8.01
DEF 14A
DEFA14A
8-K 7.01
8-K 7.01,8.01
8-K 2.02,9.01
10-K
SCHEDULE 13G —
8-K 7.01,8.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.